Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

C4 Therapeutics (CCCC) EPS (Basic) (2019 - 2025)

Historic EPS (Basic) for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to -$0.44.

  • C4 Therapeutics' EPS (Basic) fell 2571.43% to -$0.44 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.44, marking a year-over-year decrease of 2571.43%. This contributed to the annual value of -$1.52 for FY2024, which is 4307.12% up from last year.
  • According to the latest figures from Q3 2025, C4 Therapeutics' EPS (Basic) is -$0.44, which was down 2571.43% from -$0.37 recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' EPS (Basic) registered a high of -$0.26 during Q2 2024, and its lowest value of -$0.76 during Q4 2022.
  • Over the past 5 years, C4 Therapeutics' median EPS (Basic) value was -$0.51 (recorded in 2021), while the average stood at -$0.52.
  • As far as peak fluctuations go, C4 Therapeutics' EPS (Basic) soared by 9709.4% in 2021, and later plummeted by 14516.13% in 2022.
  • Quarter analysis of 5 years shows C4 Therapeutics' EPS (Basic) stood at -$0.31 in 2021, then tumbled by 145.16% to -$0.76 in 2022, then rose by 10.53% to -$0.68 in 2023, then rose by 27.94% to -$0.49 in 2024, then rose by 10.2% to -$0.44 in 2025.
  • Its last three reported values are -$0.44 in Q3 2025, -$0.37 for Q2 2025, and -$0.37 during Q1 2025.